Clinical research depicting pharmaceutical drug discovery and development

Academic-led pharma company secures £180m funding boost to translate research into medicines

A university-led biopharmaceutical company has secured almost £200m in funding to translate promising medical research into actual medicines.

The £180m investment has gone into Apollo Therapeutics, an organisation originally set up by six partners:

June 2021 saw the partnership become an independent pharmaceutical company after a £115m raise but all the founding members still remain, with King’s College London and the Institute of Cancer Research also both recently joining.

                                                                      Video credit: Canva

The funding will be used to license or acquire additional clinical stage programmes.

“This is a fantastic achievement, from a great team and great investors capitalising on a unique effective drug discovery and development model,” said Dr Iain Thomas, the head of life sciences at Cambridge Enterprise, which is the arm of Cambridge University responsible for translating research into economic and social impact.

Apollo has a scalable research and development platform for the discovery of new medicines; it selects programmes on the quality of the science and the potential to benefit the standard of patient care.

Dr Thomas added: “We are so proud to have been founders with great colleagues at Imperial College and UCL with our pharma partners AstraZeneca, GSK and Johnson and Johnson to deliver patient benefit from ground-breaking academic science.”

Image credit: iStock

NHE Nov/Dec 2023

NHE Nov/Dec 2023

AI is key in helping dementia patients live independently for longer.

The Nov/Dec 2023 edition of NHE brings you expert comment and analysis on a range of key health sector topics, from digital transformation to navigating post-pandemic challenges.


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Events

NHE has created a full calendar of events to address the most important issues that influence the delivery of healthcare services. Over 365 days you'll have the opportunity to hear from a range of highly motivating, informative and inspirational speakers. These speakers will equip you with the knowledge and unique insight to enable you to overcome the challenges that you face.

National Health Executive Podcast

Ep 39.
What makes a good NHS manager? with Anthony Painter, Director of Policy at Chartered Management Institute (CMI)

In episode 39 of the National Health Executive podcast, we were joined by Anthony Painter, who is the director of policy at the Chartered Management Institute (CMI), to discuss all things management within the UK health sector and NHS.

During the podcast, Anthony shared some of the recent research CMI conducted in partnership with the Social Market Foundation, which centred around the state of management and leadership within the NHS.

More articles...

View all